S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
NASDAQ:CORT

Corcept Therapeutics - CORT Stock Forecast, Price & News

$23.21
-0.31 (-1.32%)
(As of 12/8/2022 11:28 AM ET)
Add
Compare
Today's Range
$22.75
$23.56
50-Day Range
$22.86
$29.96
52-Week Range
$15.82
$30.14
Volume
10,066 shs
Average Volume
534,595 shs
Market Capitalization
$2.50 billion
P/E Ratio
23.21
Dividend Yield
N/A
Price Target
$32.00

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
36.1% Upside
$32.00 Price Target
Short Interest
Bearish
18.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.10mentions of Corcept Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.68 M Sold Last Quarter
Proj. Earnings Growth
-1.11%
From $0.90 to $0.89 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

240th out of 1,027 stocks

Pharmaceutical Preparations Industry

102nd out of 503 stocks

CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

StockNews.com Lowers Corcept Therapeutics (NASDAQ:CORT) to Buy
Corcept Therapeutics's Earnings: A Preview
These 3 Stocks Are Winning the Bear Market -- Here's How
Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
Corcept Therapeutics - Drug Development
CORT Crosses Above Average Analyst Target
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings
11/03/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
238
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+37.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$112.51 million
Pretax Margin
32.35%

Debt

Sales & Book Value

Annual Sales
$365.98 million
Cash Flow
$1.02 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
87,627,000
Market Cap
$2.50 billion
Optionable
Optionable
Beta
0.53

Social Links


Key Executives

  • Dr. Joseph K. Belanoff M.D. (Age 65)
    Co-Founder, Pres, CEO & Director
    Comp: $1.69M
  • Mr. Atabak Mokari (Age 45)
    CFO & Treasurer
    Comp: $687.98k
  • Dr. Hazel Hunt Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $826.67k
  • Mr. Sean MaduckMr. Sean Maduck (Age 45)
    Pres of Corcept Endocrinology
    Comp: $828.83k
  • Mr. Gary Charles Robb (Age 59)
    Chief Bus. Officer & Sec.
    Comp: $900.08k
  • Mr. Joseph Douglas LyonMr. Joseph Douglas Lyon (Age 43)
    Chief Accounting Officer
  • Ms. Amy Flood
    Chief HR & Communications Officer
  • Dr. William Guyer Pharm.D. (Age 54)
    Chief Devel. Officer













CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2023?

4 brokers have issued 12 month price objectives for Corcept Therapeutics' shares. Their CORT share price forecasts range from $30.00 to $35.00. On average, they anticipate the company's share price to reach $32.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2022?

Corcept Therapeutics' stock was trading at $19.80 at the start of the year. Since then, CORT stock has increased by 18.8% and is now trading at $23.52.
View the best growth stocks for 2022 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Wednesday, November, 3rd. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.05. The biotechnology company earned $96.13 million during the quarter, compared to analysts' expectations of $97.75 million. Corcept Therapeutics had a trailing twelve-month return on equity of 27.49% and a net margin of 29.37%. During the same quarter last year, the company posted $0.17 EPS.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $400.00 million-$410.00 million, compared to the consensus revenue estimate of $416.67 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.04%), Vanguard Group Inc. (9.60%), Renaissance Technologies LLC (6.69%), Ingalls & Snyder LLC (6.49%), Federated Hermes Inc. (5.16%) and State Street Corp (3.22%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $23.52.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.53 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $1.00 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 238 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 12/8/2022 by MarketBeat.com Staff